Group 1 - The core viewpoint of the article is that gene therapy is becoming a central focus for companies, with Hangzhou Jiayin Biotechnology Co., Ltd. officially submitting its prospectus to the Hong Kong Stock Exchange [1] - Jiayin Biotechnology, established in 2019, specializes in the development of gene therapies and oligonucleotide drugs, utilizing a dual technology platform system consisting of AAVarta and SODA [1] - The company’s research covers a wide range of diseases, including neurological disorders, ophthalmic diseases, and various hereditary and chronic conditions, resulting in a diversified product pipeline [1] Group 2 - Jiayin Biotechnology currently has 10 candidate products in development, with 4 of them already in clinical stages [2] - The core product EXG001-307, targeting SMA1 type, is set to enter Phase III clinical trials in the second half of this year and is considered the potential best-in-class candidate for SMA1 treatment in China [2] - The funds raised from the IPO will primarily be used for the further development of core products EXG001-307, key products EXG102-031 and EXG202, as well as to enhance the core technology platform and support daily operations and business expansion [2]

Domestic Financial Market - The National Development and Reform Commission is coordinating the development of charging infrastructure for new energy vehicles [5] - The Ministry of Civil Affairs is promoting the application of advanced technologies such as humanoid robots and brain-computer interfaces in the development of high-performance intelligent elderly care service robots [5] - The Ministry of Commerce is utilizing the China-US economic and trade consultation mechanism to manage differences and promote cooperation [5] Industry Latest Developments - Shenzhen is encouraging smart home systems to adapt to domestic systems and fully integrate AI, with related stocks including Ying Shi Innovation and Ruixin Microelectronics [7] - New gene therapy strategies are addressing the challenges of efficient delivery of long genes, with related stocks including Meibang Technology and Kaineng Health [7] - The surge in raw material prices and strong demand is leading to a price increase in electronic components, with related stocks including Jiang Hai Co. and Junwei Electronics [7] Focus on Listed Companies - Xinzhou Bang has submitted an application for listing on the Hong Kong Stock Exchange to strengthen its global supply layout for electronic chemicals [9] - Yunji Group plans to raise no more than 788 million yuan through a private placement to expand into intelligent manufacturing and overseas operations [9] - Lixing Co. intends to raise no more than 560 million yuan through a private placement to increase production capacity for high-end bearing rolling elements [9] - Bojie Co. is supplying liquid cooling testing equipment to N clients, with significant supply arrangements expected this year [9] Market Review and Outlook - On January 29, the three major indices showed mixed results, with the Shanghai Composite Index experiencing slight fluctuations and the Shanghai 50 Index rising over 1% [11] - The market saw rapid rotation of hotspots, with over 3,500 stocks declining, while the liquor sector surged in the afternoon [11] - The non-ferrous metals sector remained active, with copper and precious metals leading the gains, and the oil and gas sector continued its strong performance [11] - The real estate sector showed signs of rebound, while the chip industry faced declines [11] - Looking ahead, the market is expected to continue focusing on undervalued and high-certainty sectors, as the growth stocks are undergoing consolidation [11]

为此，研究团队创新性地提出了一种名为" AAVLINK"的新方法。该方法将长基因分成两段，分别 装进两个AAV中，一个AAV携带的基因片段装上特殊的"分子魔术贴"——lox位点，另一个AAV除了携 带另一半基因片段、lox位点外，还携带Cre重组酶基因。这两个AAV载体进入细胞后，Cre重组酶会精 准识别"魔术贴"，使拆分的两段基因精准重组，使其表达出完整的功能。另外，科研人员还开发了该技 术的2.0版本，解决了潜在的基因重排和免疫反应等生物安全问题，提升了该技术临床应用的安全性。 研究表明，该技术在多种细胞中能够高效重构大片段基因，且不产生截断蛋白，重组效率显著优于 传统方法。动物实验显示，该技术可以有效改善相关模型小鼠的行为和癫痫表型。 未来科研团队还将进一步探索该技术的全身递送效率、机制研究和疾病模型的建立，开展灵长类动 物模型的系统验证和临床前研究，推动该技术的转化落地。 记者从中国科学院深圳先进技术研究院获悉，该院科研团队历时五年，成功攻克了基因治疗领域利 用AAV（腺相关病毒载体）高效递送长基因的难题，提出了一种名为"AAVLINK"的新型基因治疗策 略，有望推动针对孤独症、癫痫等神经系统疾病和其 ...

新华社深圳1月28日电（记者陈宇轩）针对基因治疗中常见的长基因高效递送难题，中国科学院深圳先 进技术研究院与北京大学第一医院联合科研团队设计了一种新型基因递送方法，成功实现了11kb（kb： 千碱基对，DNA片段长度单位）长基因的安全高效递送，有望推动孤独症、癫痫等疾病的基因治疗技 术发展。相关成果1月28日在线发表于国际权威期刊《细胞》。 ...

转自：中国科学报 2020年，路中华团队联合姜玉武团队围绕这一痛点难题展开攻关。他们提出了一种名为"AAVLINK"的 新方法。该方法将长基因分成两段，分别装进两个AAV中，一个AAV携带的基因片段装上特殊的"分子 魔术贴"—lox位点，另一个AAV除了携带另一半基因片段、lox位点外，还携带Cre重组酶基因。两个装 载着基因的AAV载体进入细胞后，Cre重组酶会精准识别"魔术贴"，使拆分的两段基因精准重组，使其 表达出完整的功能。 目前，世界范围内已发现超过7000种罕见病。这类疾病大多由基因突变引发且缺乏有效治疗手段，构成 人类医学面临的重要挑战之一。近年来，基因治疗作为一种新型治疗技术，通过修复、替换或抑制致病 基因等方法，为治疗罕见病等遗传性疾病提供了新希望。 北京时间1月27日，一项发表于《细胞》的最新研究，首次提出了一种名为"AAVLINK"的新型基因治疗 策略，研究团队成功攻克了基因治疗领域利用AAV（腺相关病毒载体）高效递送长基因的难题，有望 显著推动针对孤独症、癫痫等神经系统疾病和其他遗传病的基因治疗技术的临床应用。 该研究由中国科学院深圳先进技术研究院（简称"深圳先进院"）和北京大学第一医 ...

记者从中国科学院深圳先进技术研究院获悉，该院科研团队历时五年，成功攻克了基因治疗领域利用 AAV（腺相关病毒载体）高效递送长基因的难题，提出了一种名为"AAVLINK"的新型基因治疗策略， 有望推动针对孤独症、癫痫等神经系统疾病和其他遗传病的基因治疗技术的临床应用。相关成果1月28 日在国际学术期刊《细胞》发表。 当前，世界范围内已发现超过7000种罕见病。这类疾病大多由基因突变引发且缺乏有效治疗手段，是人 类医学面临的重要挑战之一。近年来，基因治疗作为一种新型治疗技术，通过修复、替换或抑制致病基 因等方法，为治疗罕见病等遗传性疾病提供了新希望。 （文章来源：央视新闻） 为此，研究团队创新性地提出了一种名为" AAVLINK"的新方法。该方法将长基因分成两段，分别装进 两个AAV中，一个AAV携带的基因片段装上特殊的"分子魔术贴"——lox位点，另一个AAV除了携带另 一半基因片段、lox位点外，还携带Cre重组酶基因。这两个AAV载体进入细胞后，Cre重组酶会精准识 别"魔术贴"，使拆分的两段基因精准重组，使其表达出完整的功能。另外，科研人员还开发了该技术的 2.0版本，解决了潜在的基因重排和免疫反应等生物 ...

Core Viewpoint - The 2026 Chengdu High-tech Zone Industry-Capital Docking Conference aims to deepen the integration of capital and industry, focusing on the "3+6+6" modern industrial system to promote high-tech development and industrialization [2][3]. Group 1: Conference Overview - The conference will take place on January 14, 2026, at Chengdu Jingronghui, guided by the Chengdu High-tech Zone Management Committee and organized by various local financial and investment bodies [2]. - The event will feature the release of financing project lists and investment fund directions, establishing an efficient platform for industry-capital connections [2][3]. Group 2: Agenda Highlights - The agenda includes guest sign-in, opening remarks, and the release of the Chengdu High-tech Zone industry financing demand list and fund direction list [6]. - Keynote presentations will cover topics such as the Sichuan Provincial Guiding Fund System, advanced manufacturing fund, investment strategies in intelligent manufacturing, and the current state of China's biopharmaceutical industry [6][7]. Group 3: Project Roadshow - The conference will host a project roadshow featuring companies like Shanghai Xingsi Semiconductor Co., focusing on 5G/6G satellite internet, and Chengdu Haofu Technology Co., which specializes in high-end optoelectronic systems [7]. - Other participating companies include Guangdong Hanbang Laser Technology Co., Chengdu Yuetfan Innovation Technology Co., and Sichuan Zhishan Weixin Biotechnology Co., showcasing innovations in various high-tech fields [7].

Company Overview - Frontera Therapeutics is a clinical-stage gene therapy company focused on developing innovative therapies, with a commitment to providing safe, effective, and affordable gene treatment solutions globally [3] - The company has developed a differentiated pipeline of rAAV gene therapy candidates, particularly targeting ophthalmic and cardiovascular diseases, with potential for global best-in-class status [1][3] Product Pipeline - As of the last feasible date (December 16, 2025), Frontera Therapeutics has eight rAAV gene therapy candidates, including two core products: FT-002 for X-linked retinitis pigmentosa (XLRP) and FT-003 for neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) [3] - The pipeline also includes a key product, FT-001, for treating RPE65 gene biallelic mutations leading to inherited retinal disease (IRD), along with five other candidates in preclinical and early stages targeting ophthalmic, cardiovascular, and neurological diseases [3] Competitive Advantages - The company boasts a differentiated gene therapy pipeline supported by robust clinical data and global best-in-class potential, utilizing its proprietary AAVANCETM Bac/Sf9 production platform for safe, scalable, and cost-effective high-quality production [5] - Frontera Therapeutics has established a strong translational medicine and clinical operations capability, with an agile and well-coordinated R&D team of 37 members across China and the U.S. [5] - The company has achieved 12 IND approvals from the National Medical Products Administration and the FDA, making it the leading developer of rAAV gene therapies in China [6] Financial Overview - For the fiscal year ending December 31, 2023, the company reported R&D expenses of approximately $27.585 million and a net loss of $35.860 million [7][8] - The projected R&D expenses for 2024 and the first nine months of 2025 are $20.576 million and $10.969 million, respectively, with net losses of $26.464 million and $13.311 million for the same periods [7][8] Industry Overview - The global gene therapy market is expected to reach $2.8 billion in 2024, with a compound annual growth rate (CAGR) of 312.9% from 2020 to 2024 [8] - The market is projected to grow at a CAGR of 24.7% from 2024 to 2035, reaching $32 billion by 2035 [8] - The Chinese gene therapy market is anticipated to grow significantly, with a projected CAGR of 53.4% from 2025 to 2035, reaching RMB 11.6 billion by 2035 [11] Market Potential for Ophthalmic Drugs - The global ophthalmic drug market is forecasted to grow from $33.5 billion in 2020 to $41.6 billion in 2024, with a CAGR of 5.6% [15] - The Chinese ophthalmic drug market is expected to grow from RMB 18.8 billion in 2020 to RMB 29.5 billion in 2024, with a CAGR of 11.9% [15]

Core Viewpoint - Frontera Therapeutics has submitted its listing application to the Hong Kong Stock Exchange, focusing on the development of innovative rAAV gene therapies, particularly for ophthalmic and cardiovascular diseases, with a differentiated pipeline showing global best-in-class potential [1][3]. Company Overview - Frontera Therapeutics is a clinical-stage gene therapy company established in 2019, dedicated to developing safe, effective, and affordable gene therapy solutions for patients worldwide [3]. - The company's product pipeline includes eight rAAV gene therapy candidates, with two core products: FT-002 for X-linked retinitis pigmentosa and FT-003 for neovascular age-related macular degeneration and diabetic macular edema [3]. - The company has received 12 IND approvals from the National Medical Products Administration and the FDA, making it the leading developer of rAAV gene therapies in China [6]. Competitive Advantages - Frontera Therapeutics boasts a differentiated gene therapy pipeline supported by robust clinical data and global best-in-class potential [5]. - The company utilizes the AAVANCE Bac/Sf9 production platform for safe, scalable, and cost-effective high-quality production [5]. - It has a strong translational medicine and clinical operations capability, with an agile R&D team of 37 members across China and the U.S. [5]. Financial Overview - The company reported R&D expenses of approximately $27.6 million for the fiscal year 2023, with projected expenses of $20.6 million for 2024 [7]. - The net loss for the fiscal year 2023 was approximately $35.9 million, with a projected loss of $26.5 million for 2024 [8]. Industry Overview - The global gene therapy market is expected to reach $2.8 billion in 2024, with a compound annual growth rate (CAGR) of 312.9% from 2020 to 2024 [8]. - The Chinese gene therapy market is anticipated to grow at a CAGR of 53.4% from 2025 to 2035, reaching a market size of RMB 11.6 billion by 2035 [11]. - The global ophthalmic drug market is projected to grow from $33.5 billion in 2020 to $41.6 billion in 2024, with a CAGR of 5.6% [15].

Core Viewpoint - Frontera Therapeutics has submitted an application for listing on the Hong Kong Stock Exchange, indicating its intention to raise capital for further development in the gene therapy sector [1] Company Overview - Frontera Therapeutics is a clinical-stage gene therapy company focused on developing innovative therapies [1] - The company was established in 2019 and has been dedicated to the development of recombinant adeno-associated virus (rAAV) gene therapies [1] - It aims to provide safe, effective, and affordable gene therapy solutions for patients worldwide [1] Product Pipeline - Frontera Therapeutics has developed a differentiated pipeline with clinical advancements, particularly targeting ophthalmic and cardiovascular diseases [1] - The company’s pipeline is positioned to have global best-in-class potential in its therapeutic areas [1] Financial and Market Position - UBS Securities Hong Kong Limited and Haitong International Capital Limited are acting as joint sponsors for the listing application [1]